Denali Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Denali Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 04 Nov 2021 | Lorem |
| LoA Update: Sanofi/Denali multiple sclerosis candidate bumps up chances for further study after completed Phase I trial | 04 Nov 2021 | William Newton |
| F-Star works CRO Medpace for Phase I bispecific antibody study, anticipates data in 2Q/3Q19, exec says | 10 Aug 2018 | Manasi Vaidya |
| Gamida Cell initiates USD 50m financing to complete Phase III cell therapy in blood cancers – CEO | 20 Apr 2016 | Alissa Fleck |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer